Focused On-demand Library for Sodium-dependent phosphate transporter 2

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q08357

UPID:
S20A2_HUMAN

ALTERNATIVE NAMES:
Gibbon ape leukemia virus receptor 2; Phosphate transporter 2; Solute carrier family 20 member 2

ALTERNATIVE UPACC:
Q08357

BACKGROUND:
The Sodium-dependent phosphate transporter 2, identified as a key player in phosphate transport and bone quality determination, also functions as a retroviral receptor. Its ability to compensate for the loss of SLC20A1 in vascular smooth muscle cells highlights its significance in vascular calcification processes.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in idiopathic Basal ganglia calcification, a condition with diverse neuropsychiatric manifestations, Sodium-dependent phosphate transporter 2 presents a promising target for therapeutic intervention. Exploring its function further could lead to novel treatments for diseases associated with phosphate dysregulation and vascular calcification.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 1006 of 8789